糖尿病性腎臓病への挑戦　～バルドキソロンメチルの可能性～

DOI Web Site
  • 山脇 健吾
    協和キリン株式会社・研究開発本部・腎R&Dユニット

書誌事項

タイトル別名
  • Challenges in diabetic kidney disease: therapeutic potential of bardoxolone methyl

説明

<p>The prevalence of chronic kidney disease (CKD) is increasing worldwide, with primarily diabetic kidney disease (DKD), being a major public health concern. Although the detailed mechanisms of CKD progression are not fully understood, the transition to kidney failure has been suggested to occur via a final common pathway, which is thought to be associated with oxidative stress and inflammation as important factors. </p><p>The Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) pathway is a key regulator of anti-oxidative and anti-inflammatory response. A number of reports have described the association between this pathway and kidney diseases in animal studies. </p><p>Bardoxolone methyl, a semi-synthetic triterpenoids, is known to be a potent Nrf2 activator. Importantly, previous clinical trials demonstrated that bardoxolone methyl increases not only estimated glomerular filtration rate (eGFR) but measured GFR, which is a true indicator of kidney function, using the inulin clearance method in patients with DKD. A Japanese Phase 3 study is currently ongoing to assess the efficacy and safety of bardoxolone methyl in more than 1,000 patients with stages G3 and G4 DKD. </p><p>This presentation summarizes available knowledge on the therapeutic potential of bardoxolone methyl for treatment of DKD.</p>

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ